# Lecture 03: Antidepressants

## Four Properties of All Antidepressants

1. Increase activity of **serotonin (5-HT), norepinephrine (NE), and/or dopamine (DA)**
2. **All have equal efficacy** in major depression (60-70%)
3. **All have equal speed of onset** (4-8 weeks)
4. **None are addictive** or lead to drug tolerance/dependence

---

## Therapeutic Targets & Clinical Uses

| Neurotransmitter | Clinical Uses |
|------------------|---------------|
| **5-HT** | Depression, Anxiety, OCD, Bulimia |
| **NE** | Depression, Anxiety, Neuropathic pain, ADHD |
| **DA** | Depression, Weight loss, ADHD, Nicotine dependence, Parkinson's |

**Note**: DA is **NOT** used for anxiety

---

## Side Effects by Receptor Activity

| Activity | Main Side Effect |
|----------|------------------|
| **5-HT** | **Sexual dysfunction**, GI upset, CNS activation, sedation |
| **NE** | **Hypertension** |
| **DA** | CNS activation, **seizure risk** |
| **H1 antagonism** | Weight gain, sedation |
| **ACh antagonism** | "Dryness", confusion |
| **Alpha-1 antagonism** | Orthostatic hypotension |
| **Quinidine-like** | Arrhythmias (long QT) |

---

## Antidepressant Classes

### SSRIs (Selective Serotonin Reuptake Inhibitors)

| Property | Details |
|----------|---------|
| **Prototype** | Fluoxetine (Prozac) |
| **Drugs** | Fluoxetine, Sertraline, Paroxetine, Citalopram, Escitalopram, Fluvoxamine |
| **Therapeutic target** | 5-HT |
| **Side effects** | Minimal (mainly sexual dysfunction) |
| **Other uses** | Panic disorder, social phobia, OCD, PTSD, premenstrual dysphoria |
| **Note** | Most inhibit CYP450 enzymes (especially fluvoxamine, fluoxetine) |

---

### SNRIs (Serotonin-Norepinephrine Reuptake Inhibitors)

| Property | Details |
|----------|---------|
| **Prototype** | Venlafaxine |
| **Drugs** | Venlafaxine, Desvenlafaxine, Duloxetine, Levomilnacipran |
| **Therapeutic target** | 5-HT and NE |
| **Side effects** | Minimal; anorexia, somnolence, increased BP, SIADH |
| **Note** | Duloxetine associated with hepatotoxicity |

---

### TCAs (Tricyclic Antidepressants)

| Property | Details |
|----------|---------|
| **Prototype** | Imipramine (Tofranil) |
| **Drugs** | Amitriptyline, Nortriptyline, Desipramine, Imipramine, Clomipramine |
| **Therapeutic target** | 5-HT and NE |
| **Side effects** | **Everything** (H1, Alpha-1, Na channel, ACh) |
| **Toxicity** | **3 Cs: Coma, Convulsions, Cardiotoxicity** |
| **Note** | Dangerous in overdose - lethal arrhythmias |

---

### MAOIs (Monoamine Oxidase Inhibitors)

| Property | Details |
|----------|---------|
| **Prototype** | Phenelzine (Nardil) |
| **Drugs** | Phenelzine, Tranylcypromine |
| **Therapeutic target** | 5-HT, NE, and DA |
| **Side effects** | Alpha-1 (HTN), **serotonin syndrome** |
| **Note** | Rarely used; complex side effect profile; treatment-resistant depression |
| **Dietary restriction** | Avoid tyramine-containing foods (hypertensive crisis) |

---

### Atypical Antidepressants

#### Bupropion (Wellbutrin)
| Property | Details |
|----------|---------|
| **Therapeutic target** | NE and DA |
| **Side effects** | **Seizure risk**, CNS activation, insomnia, tremor |
| **Advantages** | Fewer sexual side effects, weight loss |
| **Other use** | Smoking cessation |

#### Nefazodone (Serzone)
| Property | Details |
|----------|---------|
| **Therapeutic target** | 5-HT (5-HT2 antagonist) |
| **Side effects** | Alpha-1 (sedation, postural hypotension) |
| **Advantage** | Less sexual dysfunction |

#### Mirtazapine
| Property | Details |
|----------|---------|
| **Therapeutic target** | 5-HT and NE |
| **Side effects** | H1 (weight gain, sedation) |
| **Advantage** | Less sexual dysfunction |

#### Trazodone
| Property | Details |
|----------|---------|
| **Class** | 5-HT2 antagonist |
| **Use** | Non-addictive sleep agent |
| **Side effects** | Cardiac arrhythmias, **priapism** |

---

### NMDA Antagonist

#### Dextromethorphan
- Originally developed for **cough**
- Now used for **depression** as well
- **MOA**: NMDA antagonist

---

## Summary Table: Antidepressants

| Class | Prototype | Therapeutic Target | Side Effects |
|-------|-----------|-------------------|--------------|
| **SSRI** | Fluoxetine | 5-HT | Minimal (sexual dysfunction) |
| **SNRI** | Venlafaxine | 5-HT + NE | Minimal |
| **TCA** | Imipramine | 5-HT + NE | Everything (H1, α1, Na, ACh) |
| **MAOI** | Phenelzine | 5-HT + NE + DA | α1, serotonin syndrome |
| **Bupropion** | - | NE + DA | Seizure risk |
| **Nefazodone** | - | 5-HT | α1 |
| **Mirtazapine** | - | 5-HT + NE | H1 |

---

## Drugs with Less Sexual Dysfunction
- **Nefazodone**
- **Mirtazapine**
- **Bupropion**

(These interact with 5-HT2 receptors differently than SSRIs)
